Category: News
Current Team Members
Presently, the Zanos lab is comprised of: 1 Senior Researcher 1 Research Associate / Marie Skłodowska-Curie Fellow 5 postdoctoral researchers (including 3 Marie Skłodowska-Curie Fellows) 4 Ph.D. students 4 Research Assistants We invite you to explore the profiles of each of our dedicated members, by clicking on their images! Dr. Anna Onisiforou, BA, BSc, […]
Vacancies
Got a passion for addiction neuroscience, mood disorders, or using advanced systems bioinformatics to decode brain diseases? To express your interest, please fill out the form below. Our team will review your submission, and we will contact you if your profile aligns with any opportunities. Please enable JavaScript in your browser to complete this form.Please enable […]
Welcome to the Zanos Lab – Neuroscience and Pharmacology Research in Cyprus
The Translational Neuropharmacology lab (Zanos Lab) has been established mid-2022 at the University of Cyprus. We are a dynamic interdisciplinary research team based in the city of Nicosia, Cyprus. Our diverse team brings together a wide range of expertise, including specialists in Drug Repurposing, Molecular and Behavioral Pharmacology, Drug Discovery, Neuroscience, Clinical Psychology, Medicinal Chemistry, […]
Dr. Zanos Presents Groundbreaking Research at the Mediterranean Neuroscience Society Conference
Dr. Zanos recently presented our laboratory’s groundbreaking findings at the Mediterranean Neuroscience Society conference held in Tunis (https://www.medneuroscisociety.org/mns2023_info). His presentation focused on the novel discoveries surrounding the paradigm-shifting mechanisms responsible for the rapid-antidepressant efficacy of ketamine and other potential compounds currently in clinical phase development. This presentation highlights the significant contributions of our laboratory to […]
NEW PUBLICATION: NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine
Check out our new publication in the Journal of Neuroscience: https://www.jneurosci.org/content/43/6/1038 The anesthetic and antidepressant drug ketamine is well-characterized as an NMDA receptor (NMDAR) antagonist; though, the relevance and full impact of this pharmacology to its antidepressant actions is unclear. We found that NMDAR activation, which occurs downstream of their initial actions, is necessary for […]